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Human umbilical cord blood (HUCB) has been poorly characterised 
as a source of embryonic stem cells (ESCs).  The aim of this study, therefore, 
was to evaluate HUCB as source of mesenchymal stem cells (MSCs) with 
embryonic characteristics.  HUCB was collected from consenting women 
undergoing elective caesarean sections.  HUCB was meticulously explanted 
into MesenCult media and incubated.  Qualitative and quantitative 
immunophenotyping of cells was achieved using fluorescein isothiocyanate 
(FITC) labelled antibodies (CD34, CD45, CD29, CD44, CD73 and CD105) 
phenotypic markers.  Immunocytochemistry was carried out for the human 
ESC markers CD9, stage-specific embryonic antigen-1 and 4 (SSEA-1 and 
SSEA-4), E-cadherin, Podocalyxin (PODXL), sex-determining region Y-box 
2 (SOX2), NANOG and Octamer (OCT3/4).  MSCs were cultured to induce 
differentiation into adipogenic, osteogenic, chondrogenic and neurogenic 
cells.  Immunocytochemistry was used to identify fatty acid binding protein-
4 (FABP-4), osteocalcin, aggrecan, SOX2 and oligodendrocyte-4 (Olig-4) 
markers.  The cells were strongly positive for the MSC markers CD29, CD44, 
CD73 and CD105; these cells also expressed the ESC markers CD9, SSEA-1 
and SSEA-4, E-cadherin, PODXL, SOX2, NANOG and OCT3/4.  
Additionally, the MSCs expressed the adipogenic FABP-4, osteogenic 
osteocalcin, chondrogenic aggrecan and neural Olig-4 and SOX2 markers after 
differentiation.  Therefore, HUCB is a rich source for MSCs with embryonic 
characteristics. 
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Introduction 
 Human umbilical cord blood (HUCB) has been poorly characterised as 
a source of embryonic stem cells (ESCs).  Allogeneic graft transplantation of 
Haematopoietic stem cells (HSCs) derived from HUCB has been successfully 
used in clinical practice for the last three decades.  MSCs have been isolated 
from a variety of human tissues, e.g., bone marrow (BM) (Lee et al., 2004).  
Previous studies have reported the successful isolation of MSCs from the 
umbilical cord vein, blood and both mature and progenitor foetal cells were 
found in the umbilical vein blood (Malgieri et al., 2010).  The annual rate of 
100 million human births globally suggests that HUCB could be a large and 
readily accessible stem cell source that could be acquired ethically for research 
(McGuckin et al., 2005).   
 Currently, scientists have found evidence that MSCs are present in 
some embryonic and extra-embryonic tissues. The foetal BM, blood and liver 
have been analysed for the presence of MSCs. First trimester foetal BM and 
liver generated colony-forming unit fibroblasts (CFU-F) at similar frequencies. 
The CFU-F frequency in the first trimester blood was slightly lower, although 
the MSCs could not be isolated from the second or third trimester blood and 
demonstrated that these MSCs could differentiate into different cell lineages 
(Lee et al., 2004). 
 ESCs originate from embryos from the inner cell mass (ICM) of the 
human blastocyst in 4-5 day old embryos, which were created using in vitro 
fertilisation (Rogers et al., 2004).  Within this time-scale, the dividing cells 
reach the 8/16-cell stage; thus, in theory, eight single cells can be isolated from 
the eight-cell embryo that are capable of further generating independent 
embryos if implanted in a woman's uterus at that stage (Borge, 2004).  ESCs 
are derived from totipotent cells, in the early mammalian embryo, with 
unlimited proliferation in vitro (Evans et al., 1981).  ESCs are pluripotent, i.e., 
they can differentiate into all cell types, including all three foetal germ layers 
(Tuch, 2006).  Murine ESCs were first isolated in 1981, and human ESCs 
were isolated in 1998 (Evans et al., 1981; Thomson & Marshall, 1998).  Both 
of these cell types preserve their self-renewal and potential for multilineage 
differentiation (Austin, 2001). 
 A number of human ESCs markers have been well defined.  These 
markers are expressed in undifferentiated human ESCs, and their expression is 
downgraded after differentiation.  Some genes and cell surface protein markers 
have been selected as potential universal stem cell markers for determining 
‘stemness’.  The surface markers that are used to define ESCs and the level of 
stemness in a given cell population are: CD90, which is found on thymocytes, 
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and CD34+ from prothymocytes (Cai et al., 2004); the zinc-finger protein 
Rex1 (zfp42); teratocarcinoma-derived growth factor 1 (TDGF1); SSEA-1, 
SSEA-3 and SSEA-4; lacto-series glycolipid antigen (Shevinsky et al.,1982); 
tumour rejection antigen (TRA-1-60, TRA1-81) (Thomson & Marshall, 1998; 
Scotland et al., 2009); and PODXL-like protein (Kerosuo et al, 2004).  Other 
markers include the CD9 transmembrane-4 superfamily proteins, which are 
characterised by the presence of four hydrophobic domains and play an 
integral role in sperm egg fusion (Kaji et al., 2002), and the cadherin 
transmembrane-1 family proteins, which are necessary for cell adhesion and 
cell signalling (Bryan & Stow, 2004). 
 In addition, three transcription factors are used to identify the ESCs. 
The expression of OCT-3/4 is critical to maintain embryonic-like stem cell 
self-renewal and pluripotency through an octamer motif containing a cis-
element responsible for gene transcription (Ellisd et al, 2004; McGuckin et al, 
2005).  NANOG is expressed in the ICM of the blastocyst, morula and ESCs. 
SOX2 is a transcription factor expressed in the ICM and is involved in 
developing the central nervous system (Brivanlo et al., 2003; Mitsui et al., 
2003; Eckfeldt et al., 2005; Ulloa-Montoya et al., 2005). 
 Schulz et al. (2007) identified proteins expressed by human ESCs 
while conducting a large-scale proteomic analysis of human ESCs using 
Kinexus and PowerBlot assays and subgrouped these proteins into eighteen 
categories based on their function. These protein molecules could potentially 
be beneficial for cell sorting procedures, with receptor expression leading to 
data on the self-renewal or differentiation of human ESCs through the 
identification of growth factors or bioactive peptides (Schulz et al., 2007).  
Human ESCs can become differentiated without limits and have been used in 
transplantation medicine, developmental biology and drug trials (Thomson & 
Marshall, 1998; Mitsui et al., 2003). 
Materıals And Methods 
A research laboratory safety protocol was followed.  To avoid 
contamination of the cells, the culture work was conducted within a Class II 
Microbiological Safety Cabinet, and sterile conditions were maintained.  All 
used items were correctly discarded in accordance with the laboratory safety 
protocol. The Derbyshire Research Committee provided ethical approval for 
this study. 
Collection of Umbilical Cord Blood 
 HUCB samples were collected from healthy women undergoing 
elective caesarean section at the maternity units of Lincoln County and Pilgrim 
hospitals (UK).  Signed informed consent forms were obtained from all 
participants.  Midwives collected specimens from the detached umbilical cord 
after the delivery and separation of the baby.  An in utero collection method, 
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prior to placental delivery, was used.  Once the collection was complete, the 
blood was transferred to plain tubes. 
Isolation of Cord Blood Cells (Clot Spot) Primary Culture 
HUCB clot spot was meticulously explanted into MesenCult complete 
media and incubated in a 5% CO2 incubator at 37°C (Hussain et al., 2012).  
 Identification of MSCs 
Immunofluoresence for MSCs markers 
Cytospin preparations were produced (Thermo Shandon, Runcorn) by 
centrifugation at 114 g for 5 minutes.  The adherent cells on the slides were 
then fixed with 0.3% H2O2 in 99.7% methanol (Sigma-Aldrich, Gillingham) 
for 10 minutes.  The slides were incubated with primary monoclonal 
antibodies (MoAs) against human antigen CD34, CD45 (Novocastra, Milton 
Keynes, UK), CD29, CD44 (Caltag Medsystems, Claydon, UK) and CD105 
(Immunostep, Salamanca, Spain) for 30 minutes, followed by washing with 
phosphate buffered saline (PBS).  The cells were then incubated with 
fluorescein-polyclonal rabbit anti-mouse IgG secondary antibody (1:300) for 
30 minutes in the dark.  After incubation, the slides were washed with PBS, 
and the cover slips were applied and examined under the fluorescence 
microscope (Nikon ECLIPSE E800, Digital Camera DN100, UK) 
Immunostaining (CD9, SSEA-1, SSEA-4, E-Cadherin PODXL, SOX2, 
NANOG and OCT3/4) of cells 
Following the 1st passage, HUCB MSCs were seeded and cultured in 
24-well plates. When the cells reached approximately 60% confluence, the 
cells were fixed in 0.5 mL of 4% paraformaldehyde in PBS for 20 minutes at 
room temperature and were incubated in permeabilisation and blocking 
buffer (0.5 mL of 0.3% Triton X-100 (Sigma, UK)), 1% bovine serum 
albumin (BSA), and 10% of the appropriate serum at room temperature for 
45 minutes.  The primary antibodies were diluted (1:50) in PBS containing 
1% BSA and 10% of the appropriate serum.  The cells were then incubated 
overnight at 2-8°C in 300 µL/wells and subsequently washed three times for 
5 minutes with PBS containing 1% BSA. The secondary antibodies were 
diluted (1:100) in PBS and 2% serum (the same serum used for preparing the 
blocking solution) and added to the cells at 300 µl/well in the dark for 60 
minutes at room temperature.  Ten microlitres of mounting medium 
(Calibochem, UK) was placed on a clean glass cover slip, and then the 
immunostaining was visualised under a fluorescence microscope with 
appropriate filters for each fluorophore used. 
Immunophenotyping Cell Surface Proteins (CD34, CD45, CD29, CD44 
CD73 CD105, CD9, SSEA-1, SSEA-4) 
To detect the expression of the CDs (except for CD73; R&D system, 
UK), primary FITC-labelled MoAs were used to immunophenotype the cells. 
The CD73 surface marker was assessed using phycoerythrin (PE)-conjugated 
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MoA (eBioscience, San Diego, USA).  For analysis, the cells were trypsinised, 
resuspended in ice cold PBS containing 2% foetal bovine serum (FBS), 
pelleted in 5 ml polystyrene round-bottom tubes and dissociated into single 
cell suspensions. Approximately 50 x103 cells/ml were transferred into a 5 ml 
tube, and the cells washed in 2 ml of 3% BSA/PBS followed by the addition of 
10 µl of primary antibody (FITC-labelled) to the cell suspensions and 
incubation for 30 minutes at 2-8ºC.  Following incubation, the samples were 
washed twice in 3 ml of fluorescence activated cell sorting (FACS) buffer and 
centrifuged for 3 minutes at 800 g.  The supernatants were removed, and the 
cells were resuspended in 400 µl of FACS buffer for analysis using flow 
cytometry. 
Adipogenic Differentiation  
For adipogenic differentiation, MSCs at passage 3 were plated in 24-
well plates (1.76 cm2) at 3.7 x 104 cells/well, cultured in complete MesenCult 
media and incubated overnight in a 37 °C and 5% CO2 incubator.  When the 
cells reached confluence, the complete MesenCult medium was replaced with 
0.5 ml of adipogenic differentiation medium in each well.  The medium was 
changed carefully every 3 days.  The cells were examined for differentiation 
from 7 to 14 days. 
Osteogenesis Differentiation  
MSCs at the 3rd passage were plated in 24-well plates (1.76 cm2) at a 
concentration of 7.4 x 103 cells/well and cultured in complete MesenCult 
media overnight at 37°C in a 5% CO2 and 95% air culture incubator.  When 
the cells reached 50-70% confluence, the complete MesenCult medium was 
replaced with 0.5 ml of osteogenic differentiation media in each well.  The 
media were changed every three days, and cells were examined for 
differentiation from 14 - 21 days.  
Chondrogenic Differentiation  
MSCs from cord blood at the 3rd Passage (250 x103 cells/ml) were 
transferred in their existing medium (complete MesenCult medium) to 15 ml 
conical tubes.  The cells were centrifuged at 200 g for 5 minute at room 
temperature, the supernatants were aspirated and the cells were resuspended in 
1.0 ml of D-MEM/F-12 basal medium (Gibco, UK). Subsequently, 0.5 ml of 
chondrogenic differentiation medium was added to the cell pellet and 
centrifuged at 200 g for 5 minutes at room temperature and incubated at 37°C 
in a 5% CO2 and 95% air culture incubator. The caps of tubes were loosed to 
allow gas exchange.  The cells pellet was not attached to the tube, and the 
media were changed carefully every 3 days.  The cell pellet was prepared for 
frozen sectioning within 14-21 days. 
Neurogenic Differentiation 
MSCs at passage 3 were trypsinised and resuspended in complete 
Neurocult differentiation medium (Stem Cell Technologies, UK), and 0.8x105 
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cells/ml were plated onto 8-well culture slides in complete neurocult 
differentiation medium and incubated in a 37 °C and 5% CO2 incubator. 
Approximately 350 µL of medium was removed daily and replaced with fresh 
complete Neurocult differentiation medium. The cells were examined after 5-
10 days using an inverted microscope (Nikon, UK).  
Immunocytochemistry 
The cells were fixed in 0.5 mL of 4% paraformaldehyde in PBS for 
20 minutes at room temperature and incubated in permeabilisation and 
blocking buffer ( 0.5 mL of 0.3% Triton X-100 (Sigma, UK)), 1% BSA, and 
10% of the appropriate serum at room temperature for 45 minutes.  The 
slides and wells were incubated with goat anti-mouse primary antibody 
against FABP-4 (1:50), mouse anti-human osteocalcin MoA (1:50), goat 
anti-human aggrecan polyclonal antibody (1:50) and mouse primary 
antibodies against human SOX2 and OLIG-4 (1:50) (R and D system, UK) 
overnight at 2 - 8°C followed by incubation with donkey anti-goat IgG 
rhodamine red and donkey anti-mouse IgG. Rhodamine red and donkey anti-
mouse IgM rhodamine red were used as the secondary antibodies for 1 hour 
at room temperature. The fat cells were fixed with 4% formaldehyde and 
stained with oil-red O (Sigma-Aldrich) for 10 minutes.  The bone cells were 
stained with Alizarin red (Sigma-Aldrich, UK). 
Results 
Primary Cell Culture  
The cells appeared to be spindle-like in their morphology when viewed 
under an inverted light microscope.  After 7 days, the cells spread out from the 
clots of cord blood and formed clusters.  Seven days later, the cells were 




















Figure 1: HUCB-derived MSCs with fibroblast-like morphology after 14 days of culture (20X). 
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Immunofluorescence 
 The characterisation of MSCs was conducted using a fluorescent 
microscope after labelling the extracted cells with known MSC CD markers 
conjugated with FITC.  The HSC markers CD34 and CD45 were used as 
negative controls, and cells did not fluoresce when these antibodies were used.   
Immunostaining for Embryonic Stem Cell Markers 
I mmunocytochemistry was performed following the 1st passage to 
confirm the quantitative results and revealed that the MSCs from the HUCB 
expressed the ESC markers CD9, “SSEA-1 and SSEA-4” transmembrane 
markers, E-cadherin and PODXL; and the intracellular markers SOX2, 
NANOG and OCT-3/4 (Figures 2 A, B, C, D, E, F, G and H). 
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Figure 2 (A): Expression of CD9 embryonic stem cell surface marker in MSCs isolated from 
HUCB using the immunocytochemical staining, following the 1st passage; mouse anti-CD9 
MoAb bound to the specific antigens and fluoresced subsequent to the application of donkey 
anti-mouse IgG rhodamine red X-conjugated secondary antibody (10X), (B) The expression of 
SSEA-4 embryonic stem cell surface markers in MSCs isolated from HUCB using 
immunocytochemical staining following the 1st passage; mouse anti-SSEA-4 MoAb bound to 
the specific antigens and fluoresced following the use of donkey anti-mouse IgG rhodamine 
red X-conjugated secondary antibody (10X), (C) Expression of SSEA-1 embryonic stem cell 
surface marker in MSCs isolated from HUCB using immunocytochemical staining following 
the 1st passage; mouse anti-SSEA-1 MoAb bound to the specific antigens and fluoresced 
following the use of donkey anti-mouse IgM rhodamine red X-conjugated secondary antibody 
10X, (D) The expression of E-cadherin embryonic stem cell transmembrane marker in MSCs 
isolated from HUCB using the immunocytochemical technique following the 1st passage; 
mouse anti-E-cadherin MoAb bound to the specific antigens and fluoresced following the use 
of donkey anti-mouse IgG rhodamine red X-conjugated secondary antibody  (40X), (E) 
Expression of PODXL embryonic stem cell transmembrane marker in MSCs isolated from 
HUCB using  immunocytochemical staining following the 1st passage; mouse anti-PODXL 
MoAb bound to the specific antigens and fluoresced following the use of donkey anti-mouse 
IgG rhodamine red X-conjugated secondary antibody (40X), (F) Expression of SOX2 
embryonic stem cell intracellular marker in MSCs isolated from HUCB using 
immunocytochemical staining following the 1st passage; mouse anti-SOX2 MoAb bound to 
the specific antigens and fluoresced following the use of donkey anti-mouse IgG rhodamine 
red X-conjugated secondary antibody 40X, (G) Expression of NANOG- embryonic stem cell 
intracellular marker in MSCs isolated from HUCB using immunocytochemical staining 
following the 1st passage; goat anti-NANOG polyclonal antibody bound to the specific 
antigens and fluoresced following the use of donkey anti-goat IgG rhodamine red X-
conjugated secondary antibody 40X, (H) expression of OCT-3/4 embryonic stem cell 
intracellular marker in MSCs isolated from HUCB using immunocytochemical staining 
following the 1st passage; goat anti-OCT-3/4 polyclonal antibody bound to the specific 
antigens and fluoresced following the use of donkey anti-goat IgG rhodamine red X-
conjugated secondary antibody 40X. 
 
Analysis by Flow Cytometry 
The characterisation of MSCs using flow cytometry revealed that the 
cells isolated by the previously described methods lacked expression of CD34 
and CD45. Cells were found to express CD29 (97%), CD44 (95%), CD73 
(95%) and CD105 (97%) (endoglin). MSCs also expressed the ESC markers 
CD9 (90%), SSEA-4 (90%), E-cadherin (84%), and PODXL (40%) (Figures 3 
A, B, C and D). 
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Figure 3 (A): Immunophenotyping of MSCs derived from HUCB. The cells were labelled 
following the 1st passage using mouse MoAb against the CD9 marker; rabbit anti-mouse IgG 
polyclonal secondary antibody bound to the specific antigen, and flow cytometric analysis was 
performed. Approximately 91% of the cells expressed CD9. Data are presented as the mean 
±SE of the 25 samples studied, (B) Immunophenotyping of MSCs-derived from HUCB. The 
cells were labelled following the 1st passage using mouse MoAb against the SSEA-4 marker; 
rabbit anti-mouse IgG polyclonal secondary antibody bound to the specific antigen, and flow 
cytometric analysis was performed. Approximately 90% of the cells expressed the SSEA-4. 
Data are presented as the mean ±SE of the 25 samples studied, (C) Immunophenotyping of 
MSCs derived from HUCB. The cells were labelled following the 1st passage using mouse 
MoAb against E-cadherin; rabbit anti-mouse IgG polyclonal secondary antibody bound to the 
specific antigen, and flow cytometric analysis was performed. Approximately 84% of the cells 
expressed the E-cadherin. Data are presented as the mean ±SE of the 25 samples studied, (D) 
Immunophenotyping of MSC- derived from HUCB. The cells were labelled following the 1st 
passage using MoAb against PODXL; rabbit anti-mouse IgG polyclonal secondary antibody 
bound to the specific antigen, and flow cytometric analysis was performed. Approximately 
40% of the cells expressed the PODXL. Data are presented as the mean ±SE of the 25 samples 
studied.  
Mesenchymal Stem cell Differentiation 
The differentiation capacities of the MSCs derived from HUCB were 
exposed in vitro to differentiation medium to induce adipogenic, 
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chondrogenic, osteogenic or neurogenic differentiation.  Adipocytic 
differentiation was evidenced by the formation of lipid vacuoles by oil-red O 
staining and the expression of fatty acid binding protein-4 marker (Figures 4 A 
and B).  In chondrogenic differentiation; the three-dimensional pellet cultures 
of MSCs produced aggrecan, which is characteristic of in vitro cartilage. 
These pellets did not possess the organised structure of hyaline cartilage, but a 
disorganised distribution of the chondrocyte within the cartilage-like 
extracellular matrix was observed (Figure 4 C).  The cultured MSCs were 
differentiated into osteocytes; the cell morphology started to change by day 15, 
and Alizarin red staining and osteocalcin labelling was observed by day 21 
(Figure 4 D).  Neurogenic differentiation and the expression of 
oligodendrocyte-4 and SOX2 markers were evidenced after 10 days of 
induction (Figures 4 E and F). 
 
 
Figure 4: (A) MSCs formed lipid vacuoles during adipogenic differentiation, detected using 
oil red staining (10X). (B) Immunocytochemical staining for the FABP-4 adipogenic 
differentiation marker (10X). (C) Immunocytochemical staining for the aggrecan 
chondrogenic differentiation marker (10X). (D) Immunocytochemical staining for the 
osteocalcin osteogenic differentiation marker (10X). (E) Immunocytochemical staining for 
Olig-4 neural differentiation marker (10X). (F) Immunocytochemical staining for the SOX2 
neural differentiation marker (10X). 
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Dıscussıon 
 Surface antigen expression, which allows for a rapid identification of a 
cell population, has been used extensively in immunology and haematology.  
To identify MSCs, cells should express specific cell surface markers and lack 
the HSC markers. MSCs, unlike HSCs, do not have a single definitive marker.  
Instead, MSCs are characterised by the presence or absence of a combination 
of surface phenotypic markers (Bieback et al., 2007; Tyndall et al., 2007; 
Hussain et al., 2012).  Confirmation of the identity of the cultured cells was 
accomplished using immunofluorescence and immunophenotyping.  Analysis 
by flow cytometry showed that these cells were negative for HSC markers 
(CD34 and CD45) and found to express CD29, CD44, CD73 and CD105, 
which strongly demonstrates that the cells cultured in our laboratory were 
indeed HUCB-derived MSCs/progenitor cells. 
 The aim of this study was to evaluate HUCB as a source of MSCs 
with embryonic characteristics.  The expression of the selected ESC markers 
defines the stemness of those cells. The presence of these markers on the 
surface of MSCs suggests that these cells are more primitive or earlier 
progenitors than the cells not expressing these markers.  Qualitative and 
quantitative methods were used to identify the ESC markers.  Our study 
showed that ESC markers are present on MSCs from HUCB-cultured cell 
populations. The expression of CD9, SSEA-4, SSEA-1, E-cadherin PODXL, 
SOX2, NANOG and OCT-3/4 was detected, and these proteins are known 
markers for ESCs, as CD9 is a member of the transmembrane-4 superfamily 
and is an important protein in sperm-oocyte fusion. Most of these proteins play 
a role in cellular development (Kaji et al., 2002).  It has been shown in our 
study that MSCs derived from HUCB express this marker (90%), and these 
results were confirmed using immunocytochemistry.   
 McGuckin et al. 2005 reported that cord blood stem cells were able to 
express SSEA-3 and 4, which are sialoproteins that characterise human ESCs, 
but these cells did not express SSEA-1(McGuckin et al., 2005). However, in 
this study, the flow cytometry and immunocytochemistry analyses confirmed 
the expression of SSEA-4 and SSEA-1 from HUCB MSCs. The presence of 
these markers in the MSC population suggests that the cells are in an 
undifferentiated state because their expression is down regulated following 
stem cell differentiation (Jonathan et al., 2004).  E-cadherin markers are 
transmembrane-1 proteins that are required for cell adhesion and cell 
signalling.   They are involved in directing the cells to their proper tissue 
locations during development, and they are dependent on calcium for optimal 
function; furthermore, E-cadherin proteins are responsible for the aggregation 
of the inner cell mass of the blastocyst (Bryant & Stwo, 2004).   
 Mariottim et al. (2010) reported that the MSCs derived from placenta 
and BM lack E-cadherin expression (Mariottim et al., 2010).  However, in this 
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study, 84% of the MSCs derived from HUCB expressed E-cadherin, as 
determined by immunocytochemical staining (qualitative technique).  The 
transmembrane expression of PODXL decreases during maturation of 
haematopoietic cells.  Therefore, PODXL is used as an embryonic stem cell 
marker. It has been demonstrated that PODXL mRNA is expressed in human 
CD34+ cells and in lineage-committed erythroid, megakaryocyte and myeloid 
progenitors (Kerosuo et al., 2004).  In our study, the MSCs showed low levels 
of PODXL expression (40%) compared with other markers.  
Immunocytochemistry confirmed this low level expression.  However, 
PODXL expression is still poorly defined.  
 Masahiro and colleagues (2008) showed that the MSCs from BM can 
express the SOX2 marker as a transcription factor for developing the central 
nervous system (Baer et al., 2007; Masahiro et al., 2008). The SOX2 marker 
is necessary for the pluripotency of stem cells and might play a role in the 
regulation of OCT-3/4 expression in the maintenance of multipotent 
differentiation capability through upstream transcription factors (Ellisd et al., 
2004).  In this study, we observed SOX2 expression in MSCs using 
immunocytochemical staining. The isolated MSCs also expressed other ESC 
markers, such as the transcription factor NANOG, which is expressed in the 
ICM of the blastocyst, the morula, and ESCs.  NANOG is important in 
maintaining pluripotency and works in concert with other factors, such as 
OCT-3/4 and SOX2, to maintain embryonic stem cell identity (Mitsui et al., 
2003).  In this study, we demonstrated that the expression was intracellular 
and within the nucleus. 
 The expression of OCT-3/4 is crucial to sustain the self-renewal and 
pluripotency of ESCs through an octamer motif containing a cis-element. 
OCT-3/4 is responsible for gene transcription and is expressed in totipotent 
embryonic stem and germ cells in the pre-implantation embryo (Babaie et al., 
2007).  It controls pluripotency and plays a critical role in regulating the path 
for cell differentiation (Buitrago et al., 2007).  In our study, it was 
demonstrated that the expression of OCT 3/4 was intracellular using 
immunocytochemical staining. This finding is not consistent with the results 
from previous studies (McGuckin et al., 2005).  However, our results are 
consistent with the data of Masahiro et al. (2008). 
  The biological property that most uniquely identifies MSCs is their 
capacity for multilineage mesenchymal differentiation.  Thus, cells have been 
shown to differentiate into osteoblasts, chondroblasts, neurocytes and 
adipocytes using standard in vitro tissue culture-differentiating conditions.  In 
our study, the induction of adipogenic differentiation was apparent by the 
accumulation of lipid vacuoles and expression of the adipogenic marker 
FABP-4. In osteogenic medium, which contains specific supplements, the 
MSCs were transformed from fibroblastic to an osteoblast-like morphology 
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and formed a mineralised bone matrix with calcium deposition, which was 
confirmed by the presence of positive Alizarin red staining after 21 days of 
culture. The osteogenic lineage differentiation was confirmed by labelling of 
the osteocalcin protein after 21 days of culture. Our findings are consistent 
with previously reported data (Bieback et al., 2004; Lee et al., 2004; Hussain 
et al., 2012).   
 MSCs are being used to treat articular cartilage defects. However, the 
potential of HUCB-derived cells to differentiate into chondrocytes that 
produce type II collagen has been shown by a previous study (Lee et al., 
2004).  In our study, we assayed MSCs  for chondrogenic differentiation and 
showed the ability to differentiate after 21 days in a serum-free chondrogenic 
medium.  This ability was confirmed using a special cryosectioning method to 
analyse three-dimensional cell pellets for cartilage cell protein aggrecan by 
immunocytochemistry.  Neurogenic differentiation was demonstrated by the 
expression of OLIG-4 and SOX2 neural markers. 
Conclusion 
Flow cytometry and imunoctochemistry were used to demonstrate the 
positive expression of MSCs surface markers CD29, CD44, CD73 and 
CD105 and the presence of the embryonic stem cell markers CD9, PODXL, 
E-cadherin, OCT3/4, SSEA-1, SSEA-4, NANOG and SOX2 as well as 
multilineage differentiation.  It can be concluded that HUCB is a rich source 
of MSCs with embryonic characteristics and that they may be utilised for 
clinical purposes. 
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